Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Greg22 who wrote (18600)	2/9/1999 3:05:00 PM
From: Little Gorilla	Read Replies (2) \| Respond to of 23519

Without Phase III trials? What are you talking about? Sorry, but you have just lost your credibility. N Engl J Med 1998 May 14;338(20):1397-404 Published erratum appears in N Engl J Med 1998 Jul 2;339(1):59 Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA Department of Urology, Boston University Medical Center, MA 02118, USA. BACKGROUND: Sildenafil is a potent inhibitor of cyclic guanosine monophosphate hydrolysis [corrected] in the corpus cavernosum and therefore increases the penile response to sexual stimulation. We evaluated the efficacy and safety of sildenafil, administered as needed in two sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, and mixed causes. METHODS: In a 24-week dose-response study, 532 men were treated with oral sildenafil (25, 50, or 100 mg) or placebo. In a 12-week, flexible dose-escalation study, 329 different men were treated with sildenafil or placebo, with dose escalation to 100 mg based on efficacy and tolerance. After this dose-escalation study, 225 of the 329 men entered a 32-week, open-label extension study. We assessed efficacy according to the International Index of Erectile Function, a patient log, and a global-efficacy question. RESULTS: In the dose-response study, increasing doses of sildenafil were associated with improved erectile function (P values for increases in scores for questions about achieving and maintaining erections were <0.001). For the men receiving 100 mg of sildenafil, the mean score for the question about achieving erections was 100 percent higher after treatment than at base line (4.0 vs. 2.0 of a possible score of 5). In the last four weeks of treatment in the dose-escalation study, 69 percent of all attempts at sexual intercourse were successful for the men receiving sildenafil, as compared with 22 percent for those receiving placebo (P<0.001). The mean numbers of successful attempts per month were 5.9 for the men receiving sildenafil and 1.5 for those receiving placebo (P<0.001). Headache, flushing, and dyspepsia were the most common adverse effects in the dose-escalation study, occurring in 6 percent to 18 percent of the men. Ninety-two percent of the men completed the 32-week extension study. CONCLUSIONS: Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction. Publication Types: Clinical trial Multicenter study Randomized controlled trial

To: Greg22 who wrote (18600)	2/9/1999 3:10:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Gregg, As you know, everything you are saying now is what I have been preaching for the past 12 months. So far all the lawsuits against Pfizer regarding Viagra have been individual lawsuits that I believe must be filed in the appropriate circuit court where Pfizer has its HQs(NY, NY). As these lawsuits continue to accumulate, the judge will eventually decide to turn the suits into a class action. The courts are already way too crowded for the court system to hear each individual lawsuit filed where a Viagra patient either died or had a heart attack. Pfizer is like the goose that laid the golden egg. Any lawyer would just love to have a client who took Viagra and had a coronary once a class act is filed. The scientific evidence surrounding the dangers of Viagra use in the CVD patient are indisputable. Pfizer can get away with this for only so long. I don't know why a class action wasn't filed months ago.

To: Greg22 who wrote (18600)	2/9/1999 3:13:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Greg, I am in real trouble, I need to make a lot of money quick. Can you let me know the source of your information on insider buying. Send it to me via private message so the others cannot see. Thanks, DaiS

To: Greg22 who wrote (18600)	2/9/1999 3:19:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Gregg, If you are right about current death counts and the black boxing of Viagra, it will forever change the way physicians prescribe the drug. Any physician who does prescribe Viagra to a patient with CVD will be setting him/herself up for a malpractice lawsuit if that patient has a coronary. The black box will eliminate the discretion of physicians to "use with caution.." as currently labeled. It will clearly mean that Viagra should not be used in the CVD patient PERIOD! Doctors who decide to ignore the black box will have to learn the hard way.